Vaccination with Omicron Inactivated Vaccine in Pre-vaccinated Mice Protects against SARS-CoV-2 Prototype and Omicron Variants

In response to the fast-waning immune response and the great threat of the Omicron variant of concern (VOC) to the public, we report the pilot-scale production of an inactivated Omicron vaccine candidate that induces high levels of neutralizing antibody titers to protect against the Omicron virus. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuntao, Tan, Wenjie, Lou, Zhiyong, Zhao, Yuxiu, Zhang, Jin, Liang, Hongyang, Li, Na, Zhu, Xiujuan, Ding, Ling, Huang, Baoying, Zhou, Weimin, Guo, Yancen, Yang, Zhaona, Qiao, Yuling, He, Zhenyu, Ma, Bo, He, Yao, Zhu, Di, Wang, Zhanhui, Chang, Zhen, Zhao, Xue, Wang, Wei, Xu, Ying, Zhu, Huiqin, Zheng, Xiaotong, Wang, Chenlong, Xu, Guangxue, Wu, Guizhen, Wang, Hui, Yang, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318641/
https://www.ncbi.nlm.nih.gov/pubmed/35891313
http://dx.doi.org/10.3390/vaccines10071149
Descripción
Sumario:In response to the fast-waning immune response and the great threat of the Omicron variant of concern (VOC) to the public, we report the pilot-scale production of an inactivated Omicron vaccine candidate that induces high levels of neutralizing antibody titers to protect against the Omicron virus. Here, we demonstrate that the inactivated Omicron vaccine is safe and effective in recalling immune responses to the HB02, Omicron, and Delta viruses after one or two doses of BBIBP-CorV. In addition, the efficient productivity and good genetic stability of the manufactured inactivated vaccine is proved. These results support the further evaluation of the Omicron vaccine in a clinical trial.

Ejemplares similares